Prefilled Syringe Market: Rising adoption of biologics and biosimilar therapies to Drive Market Growth to US$ 19.7 Billion by 2033

As per the latest market research by Business Market Insights (BMI), the research report "Prefilled Syringe Market Size and Forecast (2026–2033)" forecasts how the market is set to surge 125.35% by 2033. The global prefilled syringe market is driven by the increasing need for convenience, efficacy, and safety of drug delivery systems. Preference for self-injection and precision dosage is propelling its adoption. The development of biologics and injectable drugs, as well as innovations in materials used in syringes, safety and dual chamber design, is contributing to sustained market growth.

The report forecasts the market to expand from US$ 8.74 billion in 2025 to US$ 19.7 billion by 2033, registering a robust CAGR of 10.7% over the 2026–2033 period.

The global prefilled syringe market is an important segment of injectable drug delivery, providing convenient and ready-to-use solutions for administering vaccines, biologics, anticoagulants, and other injectable therapies. The applications of such devices include usage by hospitals, clinics, healthcare practitioners, and patients who require self-administration, especially in cases of chronic or acute illnesses. The demand for prefilled syringes increases due to a rise in the number of injections that require using drugs, an increased need for self-injection, and the requirement for proper dosing of medications with the reduction in medication errors. Technological innovations in terms of material design, safety system design, and double chamber design have been improving the usability and stability of the devices.

Overview of report findings

Market Growth

The prefilled syringe market is projected to grow from US$ 8.74 billion in 2025 to US$ 19.7 billion by 2033, registering a compound annual growth rate (CAGR) of 10.7% between 2026 and 2033.

The global prefilled syringe market is driven by the increasing need for convenience, efficacy, and safety of drug delivery systems. Preference for self-injection and precision dosage is propelling its adoption. The development of biologics and injectable drugs, as well as innovations in materials used in syringes, safety and dual chamber design, is contributing to sustained market growth.

Rising adoption of biologics and biosimilar therapies

The rising adoption of biologics and biosimilar therapies is a key driver of the global prefilled syringe market, as these medicines increasingly require convenient and reliable delivery systems for repeated administration. Biologics are widely used in the management of complex and chronic conditions, creating sustained demand for injectable formats that support accurate dosing and simplified administration. A rise in aging population and lifestyle diseases is adding to the patient population that needs sophisticated medicines. Also, advancements in the diagnosis of diseases allow for better recognition of the disease at an early stage. The rising awareness of physicians regarding biologic therapy and subcutaneous injection will also drive the use of prefilled syringes in healthcare facilities. Advantages of prefilled syringes are offered in case of biologic and biosimilars medicines through the provision of ready-made and measured doses. Pharmaceutical manufacturers are increasingly incorporating prefilled formats into drug development and lifecycle management strategies to improve usability, dosing consistency, handling efficiency, and patient convenience. Technological advancements in syringe materials, needle systems, safety mechanisms, and container technologies are improving compatibility with sensitive formulations and supporting more patient-centric delivery. Continued research into biologic formulations and injectable therapies is expected to expand the range of medicines suitable for prefilled delivery. As healthcare systems increasingly emphasize convenient and decentralized treatment, adoption of prefilled syringes for biologic and biosimilar therapies is expected to strengthen globally.

Increasing prevalence of chronic diseases requiring long-term treatment

The increasing prevalence of chronic diseases requiring long-term treatment is another important driver of the global prefilled syringe market, as repeated medication administration creates demand for convenient and efficient drug-delivery systems. Chronic conditions often require continuous therapeutic management, increasing the importance of accurate dosing, simplified administration, and reliable medication handling. Population aging along with lifestyle risk factors is leading to increased demand for long-term injectable drugs, whereas advances in diagnostics are facilitating early diagnosis and continuous therapy. Such trends are prompting health care professionals and drug manufacturers to opt for such systems which facilitate easy administration through the course of therapy.The growing preference for outpatient care, home-based treatment, and self-administration is further increasing the relevance of prefilled syringes. Their ready-to-use design reduces preparation steps associated with conventional vial-and-syringe systems, supporting convenient and consistent medication administration. Technological improvements in ergonomic designs, safety features, needle configurations, polymer materials, and low-dead-space systems are enhancing usability and administration efficiency. These developments are particularly important for patients requiring frequent injections, as simplified handling can improve treatment convenience and support adherence. Expansion of homecare infrastructure and decentralized healthcare services is also creating favorable conditions for adoption. As chronic disease management increasingly shifts toward patient-centered and flexible treatment models, prefilled syringes are expected to gain broader application across healthcare systems.

Geographic Insights

North America leads the prefilled syringe market due to advanced healthcare infrastructure, high adoption of injectable therapies, and strong demand for convenient drug-delivery systems. The region benefits from well-established pharmaceutical and healthcare networks, specialized treatment centers, experienced healthcare professionals, and early adoption of advanced syringe technologies. Strong regulatory frameworks and established reimbursement systems support commercialization and clinical adoption of innovative prefilled syringe products. Leading manufacturers and pharmaceutical companies are also expanding partnerships, manufacturing capabilities, and drug-delivery technologies across the region. Growing use of biologics, biosimilars, vaccines, anticoagulants, and self-administered therapies continues to support regional demand.

Europe represents the second-largest regional market, supported by an ageing population, increasing chronic disease burden, and well-developed public healthcare systems. Established healthcare infrastructure across major countries enables widespread use of injectable medicines and ready-to-use drug-delivery systems in hospitals, clinics, and homecare settings. National healthcare programs, clinical treatment practices, reimbursement mechanisms, and increasing emphasis on patient-centered care are supporting continued adoption of prefilled syringes. Manufacturers are also investing in advanced materials, safety systems, and combination delivery technologies to address evolving pharmaceutical requirements. Growing use of biologics, biosimilars, vaccines, and self-administration therapies is expected to sustain steady regional market growth.

Asia Pacific is expected to be the fastest-growing regional market due to its large patient population, rising chronic disease burden, expanding healthcare access, and increasing investment in medical infrastructure. Improvements in hospitals, pharmaceutical manufacturing capabilities, diagnostic services, and healthcare delivery networks are creating favorable conditions for wider adoption of prefilled syringe technologies. Growing physician expertise and increasing awareness of convenient drug-delivery systems are supporting acceptance across developed and emerging markets. Government initiatives aimed at strengthening healthcare access and domestic pharmaceutical capabilities are further encouraging adoption. Increasing use of biologics, vaccines, chronic disease therapies, and self-administration solutions is expected to accelerate prefilled syringe demand throughout the region.

Market Segmentation

• By product type, the prefilled syringe market is segmented into complete syringe set and components & accessories. The complete syringe set segment dominated the market in 2025.
• Based on material, the prefilled syringe market is classified into glass syringes and polymer syringes. The glass syringes segment dominated the market in 2025.
• In terms of chamber type, the prefilled syringe market is categorized into single-chamber and dual-chamber. The single-chamber segment dominated the market in 2025.
• On the basis of application, the prefilled syringe market is classified into autoimmune diseases, cardiovascular diseases, infectious diseases and vaccination, oncology, diabetes, and other applications. The autoimmune diseases segment dominated the market in 2025.
• By sales channel, the prefilled syringe market is segmented into hospitals & clinics, specialty pharmacies, online channels, and other sales channels. The hospitals & clinics segment dominated the market in 2025.

Competitive Strategy & Development

Key Players: The prefilled syringe market is populated by several key players, each contributing to its growth and innovation. Some prominent players are:

1. Becton, Dickinson and Company
2. B. Braun SE
3. Terumo Corp
4. SCHOTT Pharma AG & Co. KGaA
5. Gerresheimer AG
6. Stevanato Group S.p.A.
7. Nipro Corporation
8. West Pharmaceutical Services, Inc.
9. Fresenius Kabi AG
10. ARTE Corporation

Trending Topics: Dual-chamber prefilled syringes for lyophilized drug reconstitution, High-capacity prefilled syringes for high-viscosity biologics, Autoinjector-compatible prefilled syringe systems for self-administration, Safety-engineered prefilled syringes with integrated needle-protection mechanisms, Silicone-free prefilled syringes for sensitive biologic formulations, Polymer-based prefilled syringes for improved drug compatibility, Low-dead-space prefilled syringes for reducing drug wastage, Ready-to-use prefilled syringes for vaccines and injectable biologics, Connected prefilled syringe systems with digital monitoring features, Prefilled syringe platforms designed for combination drug-device products

Global Headlines

• B. Braun launched Rocuronium Bromide Injection in a room-temperature-stable prefilled syringe – In May 2026, B. Braun announced the U.S. launch of Rocuronium Bromide Injection as a single-dose prefilled syringe. The company stated that the FDA-approved product is room-temperature stable, eliminating refrigeration requirements and simplifying storage, distribution, and preparation for healthcare facilities.
• West Pharmaceutical Services made the West Synchrony S1 Prefillable Syringe System commercially available – In January 2026, West announced global commercial availability of the Synchrony S1 PFS System at Pharmapack 2026. The platform includes 1 mL long and 2.25 mL staked-needle options for biologics, as well as 1 mL staked-needle and Luer-lock configurations designed for vaccines.
• SCHOTT Pharma expanded its strategic partnership in India through SCHOTT Poonawalla – In May 2025, SCHOTT Pharma and Serum Institute of India announced a strategic investment involving TPG in SCHOTT Poonawalla. The joint venture manufactures prefillable syringes alongside other pharmaceutical containment and delivery products, strengthening manufacturing capabilities and supporting pharmaceutical supply in India.

Conclusion

The prefilled syringe market is poised for sustained growth, supported by increasing adoption of biologics and biosimilars, rising chronic disease burden, and growing preference for convenient self-administration. Advancements in dual-chamber systems, safety-engineered designs, high-volume syringes, and autoinjector-compatible platforms are improving drug compatibility, usability, and administration efficiency, strengthening adoption across pharmaceutical applications. North America and Europe are expected to remain stable markets due to established healthcare infrastructure, pharmaceutical capabilities, and regulatory frameworks, while Asia Pacific is positioned for faster expansion as healthcare access and pharmaceutical manufacturing capabilities improve. Emerging applications in biologics, vaccines, combination products, and home-based therapies are creating additional opportunities. Regulatory guidance addressing prefilled syringe-based combination products and delivery systems is further supporting structured product development. Overall, continued innovation and expanding injectable therapy adoption will reinforce the strategic importance and global market potential of prefilled syringes.